UNSPSC 51434951: Hydroflumethiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434951 Hydroflumethiazide/reserpine is a Commodity code that captures state and local procurement of specific pharmaceutical products, though recent solicitations show the code is being applied more broadly to advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products sourced through state and local health agencies. The issuing bodies include city fire departments (Tampa Fire Rescue through the City of Tampa Purchasing Department), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local government facilities including those in Oregon). The work being solicited spans sealed-bid procurement of individual medication line items with strict expiration and delivery requirements; exploratory market-intelligence gathering on direct-to-manufacturer prescription programs; and multi-vendor framework agreements for generic pharmaceuticals distributed through established wholesaler networks (AmerisourceBergen, Cardinal Health, Morris & Dickson) with compliance requirements including Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and FDA approval.

Geographic activity centers on Florida, Texas, and Minnesota with cooperative purchasing extending to Oregon. Recent opportunities include the City of Tampa's sealed-bid solicitation (26P00188) for Advanced Life Support Medications—specifically Labetalol, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000 and a response date of April 8, 2026, featuring a 5 percent SLBE bid discount; the Texas HHS Commission's Request for Information (HHS0017013) on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions, posted April 3, 2026, designed to inform future state procurement strategy without committed funding or timeline; and the Minnesota Department of Administration's MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026 and contract effectiveness set for July 1, 2026, requiring vendors to maintain relationships with at least two of three authorized wholesalers and pay a 3 percent administrative fee on all purchases.